OMERS ADMINISTRATION Corp Takes Position in Simulations Plus, Inc. $SLP

OMERS ADMINISTRATION Corp acquired a new position in shares of Simulations Plus, Inc. (NASDAQ:SLP) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 51,500 shares of the technology company’s stock, valued at approximately $943,000. OMERS ADMINISTRATION Corp owned approximately 0.25% of Simulations Plus at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Simulations Plus during the 2nd quarter worth approximately $706,000. Quantbot Technologies LP acquired a new stake in Simulations Plus in the second quarter valued at approximately $292,000. Ieq Capital LLC acquired a new stake in Simulations Plus in the second quarter valued at approximately $466,000. Green Alpha Advisors LLC bought a new stake in shares of Simulations Plus during the second quarter valued at approximately $249,000. Finally, First National Bank of Omaha bought a new stake in shares of Simulations Plus during the second quarter valued at approximately $346,000. 78.08% of the stock is currently owned by institutional investors and hedge funds.

Simulations Plus Stock Performance

Shares of SLP opened at $18.42 on Friday. The stock has a 50 day moving average price of $18.30 and a two-hundred day moving average price of $15.39. The firm has a market capitalization of $372.54 million, a P/E ratio of 46.05 and a beta of 1.32. Simulations Plus, Inc. has a 52 week low of $11.09 and a 52 week high of $21.01.

Simulations Plus (NASDAQ:SLP) last posted its earnings results on Thursday, July 9th. The technology company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.07. The company had revenue of $21.89 million for the quarter, compared to analyst estimates of $20.90 million. Simulations Plus had a return on equity of 13.50% and a net margin of 9.88%.

Insider Transactions at Simulations Plus

In other news, Director Walter S. Woltosz sold 4,177 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $18.44, for a total value of $77,023.88. Following the completion of the sale, the director owned 3,202,131 shares in the company, valued at $59,047,295.64. This represents a 0.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

SLP has been the topic of a number of research reports. Wall Street Zen lowered Simulations Plus from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. William Blair lowered shares of Simulations Plus from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 17th. Craig Hallum downgraded shares of Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price objective on the stock. in a report on Thursday, June 18th. Finally, Weiss Ratings upgraded shares of Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, July 10th. Seven analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $17.25.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.